Industry Perspective on First‐in‐Human and Clinical Pharmacology Strategies to Support Clinical Development of T‐Cell Engaging Bispecific Antibodies for Cancer Therapy

Documenti analoghi

• A Generalized Minimal PBPK ‐ PD Model of Bispecific Antibodies: Case Studies and Applications in Drug Development
  di: Phillip Spinosa, et al.
  Pubblicazione: (2025)
• Clinical Pharmacology Considerations for the “Off‐the‐Shelf” Allogeneic Cell Therapies
  di: Hardik Mody, et al.
  Pubblicazione: (2024)
• Mechanism‐Based Modeling Approaches to Quantify the Effect of Immunogenicity on the Pharmacokinetics of Therapeutic Proteins in Drug Development
  di: Paridhi Gupta, et al.
  Pubblicazione: (2025)
• Optimizing Clinical Translation of Bispecific T‐cell Engagers through Context Unification with a Quantitative Systems Pharmacology Model
  di: Xiaozhi Liao, et al.
  Pubblicazione: (2024)
• Clinical Pharmacology Strategies for Bispecific Antibody Development: Learnings from FDA‐Approved Bispecific Antibodies in Oncology
  di: KyoungSoo Lim, et al.
  Pubblicazione: (2024)